GlassScriptPhysician profile
Marideli Scanlan
NPI 1205027349
$444,321.26
in general payments reported to CMS, 2019-2025
46 companies · $73K in 2025
The $73K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75K · 2020: $37K · 2021: $53K · 2022: $62K · 2023: $70K · 2024: $75K · 2025: $73K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $143K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $42K · Travel and Lodging: $23K · Food and Beverage: $10K · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $142,541.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $42,322.00 |
| Travel and Lodging | $22,614.36 |
| Food and Beverage | $10,244.49 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $200,673.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $127,420.02 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $66,927.43 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26,091.18 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $17,341.85 | 2019-2021 | |
| Beta Bionics, INC. | $659.77 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amgen INC. | $603.56 | 2019-2025 | Evenity, Prolia, Tepezza |
| Sanofi-Aventis U.S. LLC | $503.81 | 2019-2025 | |
| Corcept Therapeutics | $424.69 | 2019-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $296.49 | 2021-2025 | |
| Abbott Laboratories | $281.69 | 2019-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $277.61 | 2019-2023 | Cycloset |
| Janssen Pharmaceuticals, INC | $256.23 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $208.40 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Horizon Therapeutics Plc | $176.07 | 2023 | Tepezza |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $174.73 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $156.32 | 2023-2025 | Yorvipath |
| Merck Sharp & Dohme LLC | $143.74 | 2019-2024 | Steglatro, Steglujan, Delstrigo |
| Alexion Pharmaceuticals, INC. | $118.63 | 2019-2025 | Strensiq |
| Radius Health, INC. | $117.80 | 2019 | |
| Tandem Diabetes Care, INC. | $115.56 | 2020-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $114.54 | 2019-2024 | |
| Pfizer INC. | $114.20 | 2019-2024 | |
| Amneal Pharmaceuticals LLC | $99.18 | 2019-2025 | Unithroid |
| Ibsa Pharma INC. | $97.94 | 2019-2024 | Tirosint, Licart, Tirosint |
| Regeneron Healthcare Solutions, INC. | $96.96 | 2019-2025 | Evkeeza |
| Medtronic Minimed, INC. | $90.45 | 2019-2020 | |
| Insulet Corporation | $88.76 | 2022-2025 | Omnipod |
| Esperion Therapeutics, INC. | $81.75 | 2021-2023 | Nexletol |
| Valeritas, INC. | $73.21 | 2019 | |
| Medtronic, INC. | $61.83 | 2023-2025 | Minimed 780g |
| Recordati_rare_diseases_inc. | $59.90 | 2024-2025 | Isturisa, Signifor Lar |
| Antares Pharma, INC. | $55.05 | 2023 | Tlando, Xyosted, Nocdurna |
| Neurocrine Biosciences, INC. | $52.21 | 2025 | |
| Shire North American Group INC | $51.43 | 2019 | |
| Theratechnologies INC. | $37.92 | 2022-2024 | Trogarzo, Egrifta |
| Ironwood Pharmaceuticals, INC | $32.88 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $23.21 | 2022 | |
| Halozyme INC | $18.09 | 2023 | |
| Sequel Med Tech, LLC | $17.88 | 2025 | Twiist |
| Novartis Pharmaceuticals Corporation | $15.56 | 2024 | |
| Mannkind Corporation | $15.51 | 2024 | |
| Ascensia Diabetes Care US INC. | $14.75 | 2025 | |
| Lifescan, INC. | $14.55 | 2019 | |
| Becton, Dickinson and Company | $12.30 | 2019 | |
| Cequr Corporation | $11.75 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marideli Scanlan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.